TY - JOUR
T1 - Animal models to study cognitive impairment of chronic kidney disease
AU - CONNECT Consortium
AU - Imenez Silva, Pedro H.
AU - Pepin, Marion
AU - Figurek, Andreja
AU - Gutiérrez-Jiménez, Eugenio
AU - Bobot, Mickaël
AU - Iervolino, Anna
AU - Mattace-Raso, Francesco
AU - Hoorn, Ewout J.
AU - Bailey, Matthew A.
AU - Hénaut, Lucie
AU - Nielsen, Rikke
AU - Frische, Sebastian
AU - Trepiccione, Francesco
AU - Hafez, Gaye
AU - Altunkaynak, Hande O.
AU - Endlich, Nicole
AU - Unwin, Robert
AU - Capasso, Giovambattista
AU - Pesic, Vesna
AU - Massy, Ziad
AU - Wagner, Carsten A.
PY - 2024/4/18
Y1 - 2024/4/18
N2 - Mild cognitive impairment (MCI) is common in people with chronic kidney disease (CKD), and its prevalence increases with progressive loss of kidney function. MCI is characterized by a decline in cognitive performance greater than expected for an individual age and education level but with minimal impairment of instrumental activities of daily living. Deterioration can affect one or several cognitive domains (attention, memory, executive functions, language, and perceptual motor or social cognition). Given the increasing prevalence of kidney disease, more and more people with CKD will also develop MCI causing an enormous disease burden for these individuals, their relatives, and society. However, the underlying pathomechanisms are poorly understood, and current therapies mostly aim at supporting patients in their daily lives. This illustrates the urgent need to elucidate the pathogenesis and potential therapeutic targets and test novel therapies in appropriate preclinical models. Here, we will outline the necessary criteria for experimental modeling of cognitive disorders in CKD. We discuss the use of mice, rats, and zebrafish as model systems and present valuable techniques through which kidney function and cognitive impairment can be assessed in this setting. Our objective is to enable researchers to overcome hurdles and accelerate preclinical research aimed at improving the therapy of people with CKD and MCI.
AB - Mild cognitive impairment (MCI) is common in people with chronic kidney disease (CKD), and its prevalence increases with progressive loss of kidney function. MCI is characterized by a decline in cognitive performance greater than expected for an individual age and education level but with minimal impairment of instrumental activities of daily living. Deterioration can affect one or several cognitive domains (attention, memory, executive functions, language, and perceptual motor or social cognition). Given the increasing prevalence of kidney disease, more and more people with CKD will also develop MCI causing an enormous disease burden for these individuals, their relatives, and society. However, the underlying pathomechanisms are poorly understood, and current therapies mostly aim at supporting patients in their daily lives. This illustrates the urgent need to elucidate the pathogenesis and potential therapeutic targets and test novel therapies in appropriate preclinical models. Here, we will outline the necessary criteria for experimental modeling of cognitive disorders in CKD. We discuss the use of mice, rats, and zebrafish as model systems and present valuable techniques through which kidney function and cognitive impairment can be assessed in this setting. Our objective is to enable researchers to overcome hurdles and accelerate preclinical research aimed at improving the therapy of people with CKD and MCI.
KW - chronic kidney disease
KW - mild cognitive impairment
KW - optical imaging
KW - pathophysiology
KW - rodents
U2 - 10.1152/ajprenal.00338.2023
DO - 10.1152/ajprenal.00338.2023
M3 - Article
SN - 1931-857X
VL - 326
SP - F894-F916
JO - American Journal of Physiology - Renal Physiology
JF - American Journal of Physiology - Renal Physiology
IS - 6
ER -